Text Size

Measuring Alterations of DNA in Human Blood

This study has been completed.
Sponsor:
Collaborator:
Litron Laboratories
Information provided by:
University of Rochester
ClinicalTrials.gov Identifier:
NCT00178308
First received: September 12, 2005
Last updated: September 6, 2006
Last verified: September 2006
History of Changes
  Purpose

The purpose of this research is to evaluate an automated, laser-based technique for measuring DNA damge resulting from radiation. We want to use controlled exposure on cancer patients to help develop a measurement to test people who may have been accidentally exposed to radiation.


Condition
Neoplasms

Study Type: Observational
Study Design: Observational Model: Defined Population
Time Perspective: Longitudinal
Time Perspective: Prospective

Resource links provided by NLM:

MedlinePlus related topics: Cancer
U.S. FDA Resources

Further study details as provided by University of Rochester:

Estimated Enrollment: 24
  Eligibility

Ages Eligible for Study:   21 Years to 70 Years
Genders Eligible for Study:   Both
Criteria

Inclusion Criteria:

  • Male or female, age 21 to 70 years old.
  • Patient undergoing with anti-neoplastic agent(s) known to have genotoxic activity (e.g., cyclophosphamide, 5-FU, cisplatin, Ara-C.
  • X-irradiation may be considered, so long as a substantial fraction of red marrow is exposed (e.g., femur or chest/trunk region);
  • treatment could be ongoing therapy or initial therapy.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00178308

Locations
United States, New York
University of Rochester
Rochester, New York, United States
Sponsors and Collaborators
University of Rochester
Litron Laboratories
Investigators
Principal Investigator: Yuhchyau Chen, MD, Ph.D Universtiy of Rochester, Dept of Radiation Oncology
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00178308     History of Changes
Other Study ID Numbers: URCC 1702
Study First Received: September 12, 2005
Last Updated: September 6, 2006
Health Authority: United States: Institutional Review Board

Additional relevant MeSH terms:
Neoplasms

ClinicalTrials.gov processed this record on May 23, 2013